✦ LIBER ✦

Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis

✍ Scribed by D. Rondelli; J.D. Goldberg; R. Marchioli; L. Isola; T.B. Shore; J.T. Prchal; A. Bacigalupo; A. Rambaldi; R.B. Klisovic; V. Gupta; B. Andreasson; E.P. Demakos; L.S. Price; M. Scarano; M. Wetzler; A.M. Vannucchi; V. Najfeld; G. Barosi; L.R. Silverman; R. Hoffman

Book ID: 116282877
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 57 KB
Volume: 18
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2011.12.039

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Randomized Phase II Trial of Fludarabi

A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma

✍ Bashir, Qaiser; Khan, Hassan; Thall, Peter F.; Liu, Ping; Shah, Nina; Kebriaei, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 278 KB

Phase II Trial of Reduced Intensity Busu

Phase II Trial of Reduced Intensity Busulfan / Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with AML, MDS, and ALL

✍ Chen, Yi-Bin; Li, Shuli; Del Rio, Candice; Coughlin, Erin; Ballen, Karen K.; Cut 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Rituximab in Allogeneic Hematopoietic St

Rituximab in Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia With Fludarabine + Total Body Irradiation Conditioning: Results of a Phase II Prospective Multicenter Study (Itac 02-02)

✍ M. Michallet; M. Sobh; S. Morisset; M. Mohty; G. Socie; R. Tabrizi; N. Milpied; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Phase I-II Study of Clofarabine-Melphala

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Unexpected Renal Toxicity

✍ K. van Besien; J. Kline; L. Godley; R.A. Larson; O. Odenike; E.S. Rich; W. Stock 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Non-Myeloablative (NMA) Allogeneic Hemat

Non-Myeloablative (NMA) Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation (Bu/Flu/TBI) Conditioining: Results of a Phase II Trial

✍ Brammer, Jonathan E.; Stentz, Alex; Dibb, James; Frires, Rachel; Meyers, Gabriel 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Early Results of a Phase II Study Adding

Early Results of a Phase II Study Adding Peri-Transplant Rituximab to Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients (PTS) with High-Risk Fludarabine-Refractory Chronic Lymphocytic Leukemia (Cll)

✍ M.L. Sorror; B. Storer; B.M. Sandmaier; T. Chauncey; B. Bruno; N.N.S. Andersen; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 93 KB